

U.S. Serial No.: 10/659,055
Filing Date: September 9, 2003

AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all prior versions, and listings, of claims in this application.

Listing of Claims

1. (Currently amended) A composition comprising a protein in crystalline form, wherein the protein consists of ~~SEQ. ID No. 3~~ SEQ ID NO:3, and wherein the protein crystal has a crystal lattice in a $P2_1$ space group and unit cell dimensions, +/- 5%, of $a=121.53\text{\AA}$ $b=124.11\text{\AA}$ and $c=144.42\text{\AA}$, $\alpha=\gamma=90^\circ$, $\beta=114.6^\circ$.

2-3. (Cancelled)

4. (Previously presented) A composition according to claim 1 wherein the protein crystal diffracts X-rays for a determination of structure coordinates to a resolution less than 3.0 Angstroms.

5-6. (Cancelled)

7. (Currently amended) A method for forming a crystal of a protein comprising:
forming a crystallization volume comprising a precipitant solution and a protein that consists of ~~SEQ. ID No. 3~~ SEQ ID NO:3, and wherein the protein crystal has a crystal lattice in a $P2_1$ space group and unit cell dimensions, +/- 5%, of $a=121.53\text{\AA}$ $b=124.11\text{\AA}$ and $c=144.42\text{\AA}$, $\alpha=\gamma=90^\circ$, $\beta=114.6^\circ$; and
storing the crystallization volume under conditions suitable for crystal formation of the protein.

8. (Currently amended) A method according to claim 7 wherein is expressed from a nucleic acid molecule that comprises ~~SEQ. ID No. 2~~ SEQ ID NO:2.

9. (Cancelled)

10. (Currently amended) A method according to claim 7 wherein the protein crystal diffracts X-rays for a determination of structure coordinates to a resolution less than 3.0 Angstroms.

U.S. Serial No.: 10/659,055
Filing Date: September 9, 2003

11-12. (Cancelled)

13. (Original) A method according to claim 7, the method further comprising diffracting the protein crystal to produce a diffraction pattern and solving the structure of the protein from the diffraction pattern.

14. (Cancelled)

15. (Currently amended) A ~~protein composition according~~ to claim 16 where the protein is expressed from a nucleic acid molecule that comprises ~~SEQ-ID No. 2~~ SEQ ID NO:2.

16. (Currently amended) A ~~composition comprising an isolated~~ a protein consisting of ~~SEQ-ID No. 3~~ residues 13-740 of SEQ ID NO:3.

17. (Previously presented) A method of identifying an entity that associates with a protein, comprising:

 taking structure coordinates from diffraction data obtained from a protein crystal formed according to the method of claim 7; and

 performing rational drug design using a three dimensional structure that is based on the obtained structure coordinates.

18. (Currently amended) A method according to claim 17 wherein the protein from which the protein crystal is formed is expressed from a nucleic acid molecule that comprises ~~SEQ-ID No. 2~~ SEQ ID NO:2.

19. (Cancelled)

20. (Original) A method according to claim 17, the method further comprising selecting one or more entities based on the rational drug design and contacting the selected entities with the protein.

21. (Original) A method according to claim 17, the method further comprising measuring an activity of the protein when contacted with the one or more entities.

U.S. Serial No.: 10/659,055
Filing Date: September 9, 2003

22-23. (Cancelled)

24. (New) A protein consisting of residues 39-766 of SEQ ID NO:1.

25. (New) A composition comprising a protein in crystalline form, wherein the protein consists of residues of 39-766 of SEQ ID NO:1, and wherein the protein crystal has a crystal lattice in a $P2_1$ space group and unit cell dimensions, +/- 5%, of $a=121.53\text{\AA}$ $b=124.11\text{\AA}$ and $c=144.42\text{\AA}$, $\alpha=\gamma=90^\circ$, $\beta=114.6^\circ$.

26. (New) A method for forming a crystal of a protein comprising:
forming a crystallization volume comprising a precipitant solution and a protein that consists of residues 39-766 of SEQ ID NO:1, and wherein the protein crystal has a crystal lattice in a $P2_1$ space group and unit cell dimensions, +/- 5%, of $a=121.53\text{\AA}$ $b=124.11\text{\AA}$ and $c=144.42\text{\AA}$, $\alpha=\gamma=90^\circ$, $\beta=114.6^\circ$; and
storing the crystallization volume under conditions suitable for crystal formation of the protein.